- Home
- AGIO vs AMC Comparison
AGIO vs AMC Comparison
Compare AGIO & AMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | AMC |
|---|---|---|
| Founded | 2007 | 1920 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Movies/Entertainment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.3B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | AGIO | AMC |
|---|---|---|
| Price | $26.97 | $2.00 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 6 |
| Target Price | ★ $32.13 | $3.33 |
| AVG Volume (30 Days) | 2.7M | ★ 17.1M |
| Earning Date | 10-30-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $44,791,000.00 | ★ $4,867,000,000.00 |
| Revenue This Year | $28.75 | $8.75 |
| Revenue Next Year | $139.45 | $8.01 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.26 | 9.74 |
| 52 Week Low | $22.24 | $2.05 |
| 52 Week High | $46.00 | $4.47 |
Technical Indicators
Market Signals| Indicator | AGIO | AMC |
|---|---|---|
| Relative Strength Index (RSI) | 35.66 | 30.18 |
| Support Level | $26.80 | $2.25 |
| Resistance Level | $28.61 | $2.34 |
| Average True Range (ATR) | 1.15 | 0.10 |
| MACD | 0.28 | -0.01 |
| Stochastic Oscillator | 16.59 | 4.00 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About AMC AMC Entertainment Holdings Inc.
AMC Entertainment Holdings Inc is involved in the theatrical exhibition business. It owns, operates, or has interests in theatres located in the United States and Europe. It provides amenities such as plush, power recliners, MacGuffins full bars, AMC Dine-In Theatres, and premium presentation. The company has identified two reportable segments and reporting units for its theatrical exhibition operations, U.S. markets and International markets. It derives key revenue from the U.S.